Noncardiac chest pain: current treatment.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Noncardiac chest pain (NCCP) is very common, affecting up to 25% of the adult population in the United States. Treatment for NCCP has markedly evolved in the past decade and is presently focused on gastroesophageal reflux disease (GERD) and visceral hypersensitivity. Aggressive treatment with proton pump inhibitors has become the standard of care for GERD-related NCCP. Pain modulators such as tricyclics, trazodone, and selective serotonin reuptake inhibitors are considered the mainstay of therapy for non-GERD-related NCCP Other therapeutic modalities such as botulinum toxin injections and hypnotherapy have demonstrated promise in small clinical trials.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Gastroenterol Hepatol (N Y)

Title: Gastroenterology & hepatology

Publisher:

ISSN: 1554-7914

ISSN (Print): 1554-7914

Publication date (Electronic): Apr 2007

Volume: 3

Issue: 4

Affiliations

[1 ] Dr. Schey is a Research Fellow at The Neuroenteric Clinical Research Group, where Ms. Villarreal is a Research Associate. Dr. Fass is a Professor of Medicine and Director of the GI Motility Laboratory at the University of Arizona.

Article

PMC ID: 3099272

PubMed ID: 21960837

SO-VID: 71675161-7580-49f4-9762-c6324f9ea174

History

Keywords: proton pump inhibitors,Noncardiac chest pain,tricyclics

Data availability:

Keywords: proton pump inhibitors, Noncardiac chest pain, tricyclics

Comments

Comment on this article

Cited by 3

See all cited by